Leisure Capital Management Has $775,000 Position in GSK plc (NYSE:GSK)

Leisure Capital Management lessened its stake in GSK plc (NYSE:GSK) by 16.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 20,919 shares of the pharmaceutical company’s stock after selling 4,235 shares during the quarter. Leisure Capital Management’s holdings in GSK were worth $775,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FinTrust Capital Advisors LLC increased its stake in shares of GSK by 6.9% in the third quarter. FinTrust Capital Advisors LLC now owns 4,346 shares of the pharmaceutical company’s stock worth $158,000 after acquiring an additional 281 shares during the last quarter. UMB Bank n.a. increased its position in GSK by 4.8% in the 3rd quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock worth $234,000 after purchasing an additional 297 shares during the last quarter. KCS Wealth Advisory increased its position in GSK by 1.5% in the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock worth $775,000 after purchasing an additional 314 shares during the last quarter. Caprock Group LLC raised its stake in shares of GSK by 2.8% during the 4th quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company’s stock worth $430,000 after purchasing an additional 317 shares in the last quarter. Finally, Horizon Bancorp Inc. IN lifted its holdings in shares of GSK by 8.9% during the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after buying an additional 323 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GSK. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Finally, Morgan Stanley assumed coverage on GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

GSK Stock Performance

GSK traded up $0.20 during trading on Friday, hitting $41.11. The stock had a trading volume of 2,730,464 shares, compared to its average volume of 2,904,690. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. GSK plc has a 12 month low of $33.33 and a 12 month high of $43.84. The company has a 50 day simple moving average of $41.83 and a 200-day simple moving average of $38.95. The firm has a market cap of $85.20 billion, a PE ratio of 13.66, a P/E/G ratio of 1.44 and a beta of 0.64.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. Analysts expect that GSK plc will post 4.03 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were paid a $0.3564 dividend. This is an increase from GSK’s previous quarterly dividend of $0.34. The ex-dividend date was Thursday, February 22nd. This represents a $1.43 annualized dividend and a dividend yield of 3.47%. GSK’s dividend payout ratio (DPR) is presently 52.82%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.